1. Scrip
  2. >>Business
  3. >>Strategy

GSK Puts Up (Another) Venture Fund

 
• By Randall Osborne

The name of GlaxoSmithKline's just-launched, $500 million venture fund--GSK Venture Fund--lacks pizzazz, but might do more for the pharma firm on a broader scale than its precursor, SR One. The new effort, which has yet to be formally announced, takes a more conventional--and maybe more assertive--VC approach to nailing down rights and/or starting product- and technology-focused companies.

The name of GlaxoSmithKline PLC’s just-launched, $500 million venture fund--GSK Venture Fund--lacks pizzazz, but might do more for the pharma firm on a broader scale than its precursor, SR One. The new effort, which has yet to be formally announced, takes a more conventional--and maybe more assertive--VC approach to nailing down rights and/or starting product- and technology-focused companies.

Tapped to head GSK’s new fund is Russell Greig, who has headed up both GSK’s worldwide business development and international pharmaceutical efforts. Greig will report directly to recently installed CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.